Cagrilintide Retatrutide (peptidedosingprotocols.com)

How it works

The Cagrilintide + Retatrutide stack combines two investigational weight-loss peptides that target multiple receptor pathways to enhance weight loss effects. Retatrutide (LY3437943) is a triple agonist that activates GLP-1, GIP, and glucagon receptors. GLP-1 reduces appetite and slows gastric emptying, GIP improves insulin sensitivity, and glucagon increases energy expenditure and fat oxidation. In the Phase 3 TRIUMPH-4 trial, retatrutide demonstrated a mean weight loss of 28.7% at 68 weeks, showcasing its potency as a single-agent weight-loss peptide.

Cagrilintide, on the other hand, is a long-acting amylin analog that mimics the hormone responsible for signaling fullness after meals. While retatrutide effectively addresses appetite and metabolic pathways, it does not activate the amylin pathway. By adding cagrilintide to the stack, the aim is to amplify the sensation of fullness through a different signaling route that does not overlap with the mechanisms of retatrutide. This dual approach is designed to enhance satiety and potentially lead to greater weight loss outcomes.

Both compounds also slow gastric emptying, which can prolong the feeling of fullness after meals. However, this combination may increase the risk of gastrointestinal side effects such as nausea, vomiting, and constipation. The interaction between glucagon and amylin signaling is not fully understood, as retatrutide directly activates the glucagon receptor while cagrilintide influences calcitonin-related receptors. Therefore, the combined effect on blood sugar levels remains uncertain, necessitating careful monitoring of glucose responses, especially in individuals with blood sugar concerns.

It is important to note that no clinical trial has tested the cagrilintide + retatrutide combination directly, and the dosing protocols are derived from community practices based on each compound's individual research and the CagriSema program, which combines cagrilintide with semaglutide. The rationale for this stack is to cover more biological pathways than any other current peptide stack, targeting appetite reduction, improved insulin signaling, increased energy burn, and enhanced fullness. [Source: Peptide Dosing Protocols]

Plain language: The stack combines two peptides that work together to reduce appetite and increase feelings of fullness, targeting multiple pathways for weight loss.

Who should avoid it

Individuals with active gastrointestinal disease should avoid this stack due to the potential for exacerbated GI symptoms. Those with type 1 diabetes, prior pancreatitis, a history of medullary thyroid carcinoma, or active cancer are also advised against using retatrutide, and the addition of cagrilintide raises the GI tolerance bar further. It is crucial to reassess if GI symptoms worsen during the initial weeks of treatment or if any severe side effects occur, such as sudden dysesthesia or inability to keep food down.

Standard conservative practice excludes anyone with these conditions from any retatrutide protocol, and the combination with cagrilintide may increase the risk of adverse effects. [Source: Peptide Dosing Protocols]

Plain language: People with certain medical conditions like active gastrointestinal disease or type 1 diabetes should avoid this stack.